Designing Isoform-selective Inhibitors Against Classical HDACs for Effective Anticancer Therapy: Insight and Perspectives from In Silico

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|19|7|815-824

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.7, 2018-04, pp. : 815-824

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Isoform-Selective Histone Deacetylase Inhibitors

By  

Current Pharmaceutical Design, Vol. 14, Iss. 6, 2008-02 ,pp. : 529-544

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of HDACs - Effective Drugs Against Cancer?

By  

Current Cancer Drug Targets, Vol. 10, Iss. 2, 2010-03 ,pp. : 210-228

Bentham Science Publishers

Access to resources Recommend Favorite

Actions of isoform-selective and non-selective nitric oxide synthase inhibitors on endotoxin-induced vascular leakage in rat colon

By Laszlo F.   Whittle B.J.R.  

European Journal of Pharmacology, Vol. 334, Iss. 1, 1997-09 ,pp. : 99-102

Elsevier

Access to resources Recommend Favorite

Computational Studies of Competitive Inhibitors of Nitric Oxide Synthase (NOS) Enzymes: Towards the Development of Powerful and Isoform-Selective Inhibitors

By  

Current Medicinal Chemistry, Vol. 13, Iss. 16, 2006-07 ,pp. : 1929-1946

Bentham Science Publishers

Access to resources Recommend Favorite

Further in vivo studies on attenuating morphine withdrawal: isoform-selective nitric oxide synthase inhibitors differ in efficacy

By Vaupel D.B.   Kimes A.S.   London E.D.  

European Journal of Pharmacology, Vol. 324, Iss. 1, 1997-04 ,pp. : 11-20

Elsevier

Access to resources Recommend Favorite